Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Allergan
Botulinum toxin Type A 300U has been discontinued from the study after regulatory approval of botulinum toxin Type A 200U. Patients remaining in the study who were allocated to receive botulinum toxin Type A 300U at treatment 2 (and had not yet received it) will receive botulinum toxin Type A 200U instead.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Urinary incontinence as a result of neurogenic overactive bladder due to spinal cord injury or multiple sclerosis
Inadequate response to anticholinergic medication used to treat overactive bladder.
Neurological respiratory impairment and abnormal pulmonary function test results
You may not be if
History or evidence of pelvic or urologic abnormality
Previous or current diagnosis of bladder or prostate cancer
Symptomatic or untreated urinary tract infection at time of enrollment
